← Home
Eisai 
Pharma / Pharmaceuticals, Healthcare
Press Releases
| Date | Press release |
|---|---|
| 2024-07-26 07:49:00 | Eisai Will Seek Re-examination Of Chmp Opinion FÖr Lecanemab Stockholm , july 26, 2024 /prnewswire/ -- bioarctic ab’s (publ) (nasdaq stockholm: bioa b) partner eisai announced today that they will request re-examination of the committee for medicinal products for human use (chmp’s) negative opinion posted today on the marketing authorization approval (maa) for lecanemab as treatment for alzheimer’s disease in the eu. \"we are surprised and very disappointed by the chmp’s opinion posted today. |
| 2024-07-25 00:58:00 | Dassault SystÈmes: Eisai Selects Medidata’s Clinical Data Studio To Enhance And Modernize Clinical Trial Efficiency And Patient Experience Eisai selects medidata’s clinical data studio to enhance and modernize clinical trial efficiency and patient experience |
| 2024-06-09 22:55:00 | Fda Accepts Filing Of Leqembi® (lecanemab-irmb) Sbla For Iv Maintenance Dosing For The Treatment Of Early Alzheimer’s Disease Stockholm , june 10, 2024 /prnewswire/ -- bioarctic ab’s (publ) (nasdaq stockholm: bioa b) partner eisai announced today that that the u.s. food and drug administration (fda) has accepted eisai’s supplemental biologics license application (sbla) for less frequent monthly lecanemab-irmb (u.s. brand name: leqembi) intravenous (iv) maintenance dosing. a prescription drug user fee act (pdufa) action date is set for january 25, 2025. |
| 2024-06-09 19:37:00 | Fda Accepts Eisai’s Filing Of Leqembi® (lecanemab-irmb) Supplemental Biologics License Application For Iv Maintenance Dosing For The Treatment Of Early Alzheimer’s Disease Tokyo and cambridge, mass., june 09, 2024 (globe newswire) -- eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that the u.s. food and drug administration (fda) has accepted eisai’s supplemental biologics license application (sbla) for monthly lecanemab-irmb (u.s. brand name: leqembi®) intravenous (iv) maintenance dosing. a prescription drug user fee act (pdufa) action date is set for january 25, 2025. leqembi is indicated for the treatment of alzheimer’s disease (ad) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early ad). |
| 2024-06-09 19:30:00 | Fda Accepts Eisai’s Filing Of Leqembi® (lecanemab-irmb) Supplemental Biologics License Application For Iv Maintenance Dosing For The Treatment Of Early Alzheimer’s Disease Tokyo and cambridge, mass. , june 9, 2024 /prnewswire/ -- eisai co., ltd. |
| 2023-03-23 08:08:00 |
|
| 2023-01-06 23:30:00 |
|
| 2023-01-06 14:30:00 |
|
| 2022-12-12 09:00:00 |
|
| 2022-11-23 18:30:00 |
|
| 2022-08-03 19:32:00 |
|
| 2022-06-02 19:30:00 |
|
| 2021-12-17 06:44:00 |
|
| 2021-11-11 11:20:00 |
|
| 2021-07-22 07:32:00 |
|
📰 Browse additional press releases for Eisai!
Sign up for free or log in
Have you heard about our short Daily Video Newsletter?
Find out more
Frequently Asked Questions
📊 What exactly does InsightfulValue do?✖
InsightfulValue helps investors analyze public companies with smart tools, highlighting undervalued opportunities based on solid data, not hype.
🔍 How do you identify undervalued stocks?✖
We use key metrics like P/E, P/B, cash flow, debt levels, and more—blended with value-investing principles and proprietary scoring.
📈 Do you provide real-time stock data?✖
We focus on fundamental analysis and not real-time price feeds. Our data is updated regularly for financials, ratios, and risk metrics.
🧠 Do I need investing experience to use InsightfulValue?✖
Not at all. Our platform is built to be beginner-friendly while still offering advanced tools for experienced investors.
💡 What makes your analysis different?✖
We strip away the noise and show only meaningful data—SWOTs, margin of safety, 30-year financial trends, peer comparisons, and more.
💰 Is there a free version of InsightfulValue?✖
Yes! You can explore key features for free. If you want full access to all companies and premium tools, we offer an upgrade.
📚 Where do you get your financial data?✖
We use trusted financial data providers and cross-reference sources to ensure accuracy and depth.
🛠️ What kind of tools are included in premium access?✖
Premium users get advanced filters, full financial history, fair value estimations, risk flags, and investment checklists.
🔒 How secure is my data on InsightfulValue?✖
We take data privacy seriously. All information is encrypted and we never sell your personal data.
🧾 Can I use InsightfulValue for due diligence?✖
Absolutely. Our tools are designed to simplify in-depth research and help you confidently evaluate companies before investing.